Goodman, L.S., AND Gilman, A.: The Pharmacologic Basis of Therapeutics, 2nd edition, p. 1520. Macmillan, New York, 1955.
2.
Clatanoff, D.V. , Triggs, P.O., AND Meyer, O.O.: Clinical experiences with Warfarin and warfarin sodium. Arch. Int. Med., 94: 213, 1954.
3.
Pollock, B.E. : Clinical experience with warfarin (Coumadin) sodium, a new anticoagulant. J. A. M. A., 159: 1094, 1955 ; and The early management of myocardial infarction, J. A. M. A.161: 404, 1956.
4.
Shapiro, S.: Warfarin sodium derivative: (Coumadin sodium)—an intravenous hypoprothrombinemia-inducing agent. Angiology4: 380, 1953; and The hypoprothrombinemia-inducing activity of warfarin (Coumadin) sodium. J. Kansas M. Soc. , 55: 687, 1954 .
5.
Wolff, J.M., Barker, N.W., Gifford, R.W., AND Mann, F.D.: Experiences with a new intravenous coumarin anticoagulant (warfarin sodium derivative). Proc. Staff Meet. Mayo Clin., 28: 489, 1953.
6.
Nichol, E.S. , In Current Therapy, 1954, p. 199. W. B. Saunders Co., Philadelphia, and Nichol, E.S., Philips, W.C., and Jenkins, V.E.: Anticoagulants in coronary heart disease. M. Clin. North America38: 399, 1954.
7.
Freeman, D.J. , AND Meyer, O.O.: Rectal administration of warfarin (Coumadin) sodium (sodium [3(2-acetonyl-benzyl)-4-hydroxycoumarin]). Proc. Soc. Exper. Biol. &Med., 92: 52, 1956.
